Premium
Feline pemphigus foliaceus in non‐specialist veterinary practice: a retrospective analysis
Author(s) -
Coyner K.,
Tater K.,
Rishniw M.
Publication year - 2018
Publication title -
journal of small animal practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.7
H-Index - 67
eISSN - 1748-5827
pISSN - 0022-4510
DOI - 10.1111/jsap.12869
Subject(s) - medicine , pemphigus foliaceus , cats , adverse effect , prednisolone , glucocorticoid , ciclosporin , retrospective cohort study , dermatology , chemotherapy , immunology , antibody , autoantibody
Objectives To characterise the signalment, clinical presentation and therapy of pemphigus foliaceus in cats treated by primary care practitioners. Materials and Methods Retrospective evaluation of patient and treatment factors with the following case outcomes: remission (achieving remission, time to remission), treatment‐related adverse effects (number, severity) and final disease outcome (medical control, cure, death or euthanasia). Results Data were obtained from 48 cats with biopsy‐confirmed pemphigus foliaceus managed by practitioners from six countries and 47 hospitals. Clinicians prescribed oral prednisolone most commonly for immunosuppression (median dose 2·2 mg/kg/day). Disease remission information was available in 40 cats; 90% achieved disease remission, which did not appear related to the doses of oral glucocorticoid administered in this study. Disease relapse occurred in 29 (73%) cats after achieving remission, necessitating medication adjustments. Severe treatment‐related adverse effects occurred in eight cases, including both cats treated with long‐acting injectable glucocorticoids. Of 31 cats treated with glucocorticoid monotherapy, 27 achieved remission, as did eight of 11 ciclosporin plus glucocorticoid‐treated cats. Eleven cats experienced adverse effects: five receiving ciclosporin plus glucocorticoid and six receiving glucocorticoid monotherapy. Clinical Significance Pemphigus foliaceus remission with treatment is highly likely in cats but relapse is common, necessitating close monitoring and individualised therapy modifications. Clinicians should focus on the judicious use of glucocorticoids to minimise treatment‐related adverse effects, such as avoiding injectable glucocorticoids, combining glucocorticoids with steroid‐sparing medications, and regularly rechecking patients to adjust drug dosages in response to disease status.